Publication:
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.

Loading...
Thumbnail Image

Date

2022-03-17

Authors

Martínez-Arranz, Ibon
Bruzzone, Chiara
Noureddin, Mazen
Gil-Redondo, Ruben
Mincholé, Itziar
Bizkarguenaga, Maider
Arretxe, Enara
Iruarrizaga-Lejarreta, Marta
Fernández-Ramos, David
Lopitz-Otsoa, Fernando

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6 , and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A. Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.

Description

MeSH Terms

Animals
Apolipoproteins B
Cardiovascular Diseases
Cholesterol, VLDL
Heart Disease Risk Factors
Lipoproteins, VLDL
Liver
Mice
Non-alcoholic Fatty Liver Disease
Phospholipases
Risk Factors
Triglycerides

DeCS Terms

CIE Terms

Keywords

Citation